Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tomoe Akagami
Chemoradiotherapy Followed by Durvalumab in Patients With Unresectable Advanced Non‐small Cell Lung Cancer: Management of Adverse Events
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Related publications
P2.01-71 Clinical Outcome of Induction Chemoradiotherapy Followed by Surgery for the Patients With cN2 Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Management of Patients With Advanced Non-Small Cell Lung Cancer: Role of Gefitinib
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
A Case of Small Cell Lung Cancer Treated With Chemoradiotherapy Followed by Photodynamic Therapy
Thorax
Pulmonary
Respiratory Medicine
P2.17-05 Consolidation Chemotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiotherapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Association Between Adverse Events and Quality of Life in Patients Treated With Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Unresectable Stage III Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Advanced Non-Small Cell Lung Cancer in Elderly Patients
Breathe
Pulmonary
Respiratory Medicine
Proactive Management Strategies for Potential Gastrointestinal Adverse Reactions With Ceritinib in Patients With Advanced ALK-positive Non-Small-Cell Lung Cancer
Cancer Management and Research
Oncology